These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

491 related items for PubMed ID: 18853664

  • 1. [Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline].
    Renke M, Rutkowski P, Tylicki L, Zietkiewicz M, Larczyński W, Rutkowski B.
    Przegl Lek; 2008; 65(6):312-4. PubMed ID: 18853664
    [Abstract] [Full Text] [Related]

  • 2. [Pentoxifylline old drug or new hope for nephrology?].
    Renke M, Rutkowski P, Tylicki L, Zietkiewicz M, Larczyński W, Rutkowski B.
    Przegl Lek; 2008; 65(7-8):358-61. PubMed ID: 19004236
    [Abstract] [Full Text] [Related]

  • 3. Will the addition of pentoxifylline reduce proteinuria in patients with diabetic glomerulosclerosis refractory to maximal doses of both an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker?
    Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB.
    J Nephrol; 2007; 20(4):410-6. PubMed ID: 17879206
    [Abstract] [Full Text] [Related]

  • 4. Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.
    Renke M, Tylicki L, Rutkowski P, Wojnarowski K, Lysiak-Szydlowska W, Rutkowski B.
    Scand J Urol Nephrol; 2005; 39(6):511-7. PubMed ID: 16303729
    [Abstract] [Full Text] [Related]

  • 5. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
    Trimarchi H, Muryan A, Young P, Forrester M, Iotti A, Pereyra H, Lombi F, Seminario O, Alonso M, Iotti R.
    Medicina (B Aires); 2007; 67(5):445-50. PubMed ID: 18051227
    [Abstract] [Full Text] [Related]

  • 6. Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial.
    Lin SL, Chen YM, Chiang WC, Wu KD, Tsai TJ.
    Am J Kidney Dis; 2008 Sep; 52(3):464-74. PubMed ID: 18617301
    [Abstract] [Full Text] [Related]

  • 7. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 8. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease.
    Matsuda H, Hayashi K, Saruta T.
    J Hum Hypertens; 2003 Apr; 17(4):271-6. PubMed ID: 12692572
    [Abstract] [Full Text] [Related]

  • 9. Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study.
    Renke M, Tylicki L, Rutkowski P, Knap N, Zietkiewicz M, Neuwelt A, Aleksandrowicz E, Łysiak-Szydłowska W, Woźniak M, Rutkowski B.
    Acta Biochim Pol; 2010 Apr; 57(1):119-23. PubMed ID: 20309434
    [Abstract] [Full Text] [Related]

  • 10. Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with Angiotensin-converting enzyme inhibitors.
    Seeman T, Pohl M, Misselwitz J, John U.
    Kidney Blood Press Res; 2009 Apr; 32(6):440-4. PubMed ID: 20016211
    [Abstract] [Full Text] [Related]

  • 11. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.
    Agarwal R, Siva S, Dunn SR, Sharma K.
    Am J Kidney Dis; 2002 Mar; 39(3):486-92. PubMed ID: 11877567
    [Abstract] [Full Text] [Related]

  • 12. Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy.
    Horita Y, Taura K, Taguchi T, Furusu A, Kohno S.
    Nephrology (Carlton); 2006 Oct; 11(5):462-6. PubMed ID: 17014562
    [Abstract] [Full Text] [Related]

  • 13. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial.
    Perkins RM, Aboudara MC, Uy AL, Olson SW, Cushner HM, Yuan CM.
    Am J Kidney Dis; 2009 Apr; 53(4):606-16. PubMed ID: 19216016
    [Abstract] [Full Text] [Related]

  • 14. Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases.
    Bianchi S, Bigazzi R, Campese VM.
    Am J Kidney Dis; 2010 Apr; 55(4):671-81. PubMed ID: 20097461
    [Abstract] [Full Text] [Related]

  • 15. Add-on angiotensin receptor blockade with maximized ACE inhibition.
    Agarwal R.
    Kidney Int; 2001 Jun; 59(6):2282-9. PubMed ID: 11380832
    [Abstract] [Full Text] [Related]

  • 16. Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis.
    Renke M, Tylicki L, Rutkowski P, Rutkowski B.
    Scand J Urol Nephrol; 2004 Jun; 38(5):427-33. PubMed ID: 15764256
    [Abstract] [Full Text] [Related]

  • 17. Acute renal failure during lisinopril and losartan therapy for proteinuria.
    Hanevold CD.
    Pharmacotherapy; 2006 Sep; 26(9):1348-51. PubMed ID: 16945058
    [Abstract] [Full Text] [Related]

  • 18. Dual renin-angiotensin system blockade at optimal doses for proteinuria.
    Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D.
    Kidney Int; 2002 Sep; 62(3):1020-5. PubMed ID: 12164886
    [Abstract] [Full Text] [Related]

  • 19. The effect of N-acetylcysteine on proteinuria and markers of tubular injury in non-diabetic patients with chronic kidney disease. A placebo-controlled, randomized, open, cross-over study.
    Renke M, Tylicki L, Rutkowski P, Larczyński W, Aleksandrowicz E, Lysiak-Szydłowska W, Rutkowski B.
    Kidney Blood Press Res; 2008 Sep; 31(6):404-10. PubMed ID: 19092257
    [Abstract] [Full Text] [Related]

  • 20. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
    Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J.
    Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.